Actos Bladder Cancer
On June 15, 2001, the Food and Drug Administration in a safety announcement stated that the use of Actos for a over a year may be linked to the development of bladder cancer. This addition to the drug's warnings followed similar announcements in France and Germany.
Actos (Pioglitazone) is a type 2 diabetes drug manufactured by the Japanese company, Takeda International. It is a thiazolidinedione, a class of drugs prescribed to make a patient's cells more receptive to insulin with the intention of reducing the effects of type 2 diabetes.
Type 2 diabetes is chronic medical condition caused by the body's inability to regulate insulin. This inability to process insulin results in hyperglycemia or high levels of sugar in the blood. Type 2 diabetes, if untreated, results in other medical conditions with significant symptoms to a person.
Symptoms of Bladder Cancer Include:
- Blood in the urine;
- Pain while urinating;
- Inability to void; or
- Voiding in small frequent amounts.
Treatment Modalities depending on the stage and involvement of the cancer include:
- Surgery to remove the cancer;
- chemotherapy; and
In addition to the cancer, patients undergo medical procedures, have anxiety about the diagnosis and prognosis and recurrence.
If you are a loved one has been diagnosed with bladder cancer while using Actos, contact Actos lawyer Mike Sudekum for more information.